Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.8%
Thu, 7 Nov 14:28

Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.8%Image source: bluebay2014/www.istockphoto.com

Panacea Biotech share price has plunged 5% and is presently trading at Rs 367.8.

Meanwhile, the BSE HEALTHCARE index is at 44,112.3 (down 0.8%).

Among the top losers in the BSE HEALTHCARE index today are Glenmark Pharma (down 6.9%) and FDC (down 5.1%).

APOLLO HOSPITALS (up 6.5%) and CAPLIN POINT (up 2.9%) are among the top gainers today.

Over the last one year, Panacea Biotech has moved up from Rs 158.7 to Rs 367.8, registering a gain of Rs 209.1 (up 131.7%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,089.2 to 44,112.3, registering a gain of 57.0% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 218.3%), SUVEN PHARMACEUTICALS (up 124.9%) and Glenmark Pharma (up 118.1%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,532.8 (down 1.1%).

The top losers among the BSE Sensex today are Tech Mahindra (down 2.6%) and Tata Motors (down 2.3%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 24,188.8 (down 1.2%). Hindalco and Trent are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,958.7 to 79,532.8, registering a gain of 14,574.2 points (up 22.4%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2024, Panacea Biotech reported 95.5% increase in net profit to Rs -15 million compared to net loss of Rs 337 million during FY23. Revenue of the company grew 21.6% to Rs 5,592 million during FY24.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -79.4.


Equitymaster requests your view! Post a comment on "Panacea Biotech Plunges 5%; BSE HEALTHCARE Index Down 0.8%". Click here!